Context Therapeutics is developing next-generation therapies to treat female cancers and other solid tumors. Advancing both bispecific antibodies and small molecule medicines, Context is targeting female cancers including breast, ovarian and endometrial cancers. Bispecific antibodies can function by recognising antigens present on both tumor cells and immune cells. Context’s lead candidate, CTIM-76, recognises Claudin-6 which is overexpressed in many female cancers. Context’s lead oral therapeutic, ONA-XR, is a progesterone receptor (PR) antagonist that is currently being tested in clinical trials. The PR receptor plays a key role in hormonally-regulated tissues such as the breast, ovaries and endometrium and there is currently no treatment for PR+ cancers.

Context Therapeutics

Short description:

Drug notes:

Long description:

Jobs: